TSPY11P

Across TCGA pan-cancer cohorts, TSPY11P RNA is linked to patient survival in 11 of 34 cancer types, making it the most broadly survival-associated TSPY11P data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher TSPY11P RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated TSPY11P expression acts as an unfavorable survival marker, although some lineages such as SKCM and TGCT show a favorable association.

LIHC, BRCA, and ESCA are the cancer types where TSPY11P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Tertile	All	0.159	0.575	<.001	72	view →
BRCA	OS	Tertile	All	0.120	0.578	.004	66	view →
ESCA	OS	Tertile	IV	0.095	0.512	.008	36	view →
CESC	OS	Tertile	All	0.261	0.798	.006	36	view →
MESO	DFS	Tertile	IV	0.079	0.414	.004	18	view →
STAD	OS	Tertile	All	0.142	0.730	<.001	18	view →
SKCM	DFS	Tertile	II,III,IV	0.615	0.210	.019	12	view →
HNSC	DFS	Tertile	IV	0.206	0.583	.044	9	view →
TGCT	DFS	Quartile	All	0.879	0.631	.037	6	view →
LGG	OS	Tertile	All	0.876	0.768	.030	5	view →
GBM	OS	Tertile	All	0.440	0.175	.044	3	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

TSPY11P–LIHC (DFS)

Open the LIHC breakdown →